The Swiss drugmaker will show late-stage results for three experimental cancer treatments at Europe’s biggest oncology meeting. The full data has not yet been published, and the claims so far come from the company itself.
Roche ESMO 2026 plans were announced on Monday, October 19, 2026, when the company said it will present new late-stage trial results at the European Society for Medical Oncology (ESMO) Annual Meeting. The congress runs from October 23 to 27 in Madrid and includes two late-breaking abstracts from Roche, covering lung cancer, breast cancer and several hard-to-treat tumours. Because the meeting has not yet begun, the detailed figures have not been shown, and what is known comes from Roche’s announcement and early reporting of it.
Roche ESMO 2026: the lung cancer result to watch
The most closely watched lung cancer result comes from the phase III Krascendo 1 trial. It tested divarasib, a targeted drug, in adults with previously treated, advanced non-small cell lung cancer driven by a KRAS G12C mutation. This is a specific genetic change in tumour cells, and a small group of existing drugs, including sotorasib and adagrasib, already target it.
According to Roche, divarasib performed better than those first-generation treatments in a direct comparison, and Reuters reported the same claim. The result will be presented as a late-breaking abstract in a Presidential Symposium, one of the congress’s most prominent sessions. Until the numbers are published, it is not possible to say how large the advantage is, which patients gain most or what side effects appeared.
Breast cancer: giredestrant and quality of life
In breast cancer, Roche will present patient-reported outcomes from the phase III lidERA study of giredestrant, an investigational oral drug that blocks and breaks down the oestrogen receptor. The trial involves early-stage, oestrogen receptor-positive, HER2-negative breast cancer. Roche says this is the subtype in which more than 90% of cases are diagnosed at stages I to III.
The company says giredestrant improved outcomes compared with standard endocrine therapy without harming tolerability or quality of life. For people who may take hormone-blocking treatment for years, how they feel day to day is a central question, so these patient-reported results may matter as much as the survival figures. Roche will also show updated interim data from the MORPHEUS trial, which tests giredestrant combined with inavolisib in locally advanced or metastatic disease.
Tam-Peli and harder-to-treat tumours
The third drug is Tam-Peli, an experimental antibody-drug conjugate aimed at a protein called B7-H3. Antibody-drug conjugates attach a chemotherapy agent to an antibody so that it is delivered more directly to cancer cells. Roche will present late-breaking interim phase III results in heavily pretreated nasopharyngeal carcinoma, a cancer of the upper throat behind the nose, with the pivotal data reported in Chinese patients.
Roche also says a separate phase III trial, TAISHAN-302, in second-line small-cell lung cancer met all three of its main goals at a first interim analysis. Those results were presented in September at the World Conference on Lung Cancer. Roche develops Tam-Peli outside mainland China, Hong Kong and Macau, and says it plans global trials across several tumour types, so its use in other regions depends on future studies.
What the Roche ESMO 2026 data does and does not mean
These are company-reported findings, and interim results can change as trials continue. Presentation at a conference is not the same as regulatory approval, so patients cannot yet expect these treatments to become available simply because the data will be shown. Anyone affected by these cancers should speak to their oncologist about treatment options rather than relying on a congress announcement.
The next confirmed step comes in Madrid between October 23 and 27, when the full results are scheduled to be shown and independent specialists can begin to assess them. For more health and medical coverage, visit the Human Crisis News homepage. The original announcement is available in Roche’s press release.